A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis comorbidity (CAIN457A2318)
BİLAÇ C., ŞAHİN M. T., ÖZTÜRKCAN S.
Diğer Uluslararası Fon Programları, 2017 - 2018
- Proje Türü: Diğer Uluslararası Fon Programları
- Başlama Tarihi: Şubat 2017
- Bitiş Tarihi: Kasım 2018